Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease)
HER2-positive metastatic or locally advanced breast cancer
For MBC participants:
Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease, amenable for treatment with docetaxel
History of disease progression within 3 months prior to study entry
For LABC participants:
Newly diagnosed locally advanced breast cancer, Stage IIA-IIIC (American Joint Committee on Cancer \[AJCC\] staging system)
You may not be if
Significant cardiac disease
Inadequate bone marrow, liver or renal function
For MBC participants:
Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastases
Brain metastases that are untreated, symptomatic or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment.
For LABC participants:
Clinically or radiologically detectable metastasis (M1 disease)
Participants for whom surgery as primary intent procedure is the best option to treat their disease
Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease
Clareo Health | A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
